Haisco steps onto global stage with blue chip NewCo deal

Haisco is introducing itself to Western investors on the eve of the J.P. Morgan Healthcare Conference via a NewCo Model deal backed by $200 million from a Frazier-led syndicate. The company is built around a PDE3/4 inhibitor designed to compete with the COPD asset at the center of Merck’s $10 billion acquisition of Verona last year.

Haisco Pharmaceutical Group Co. Ltd. (SZSE:002653) is spinning out its Phase II PDE3/4 inhibitor HSK39004, now known as AN01, into a new company, AirNexis Therapeutics...